CL2022000967A1 - Composiciones y métodos para el tratamiento de enfermedades hepáticas - Google Patents

Composiciones y métodos para el tratamiento de enfermedades hepáticas

Info

Publication number
CL2022000967A1
CL2022000967A1 CL2022000967A CL2022000967A CL2022000967A1 CL 2022000967 A1 CL2022000967 A1 CL 2022000967A1 CL 2022000967 A CL2022000967 A CL 2022000967A CL 2022000967 A CL2022000967 A CL 2022000967A CL 2022000967 A1 CL2022000967 A1 CL 2022000967A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
methods
liver diseases
liver
Prior art date
Application number
CL2022000967A
Other languages
English (en)
Inventor
Gutierrez Alejandro Soto
Aaron Bell
Navarro Nicolas Fraunhoffer
Lepe Jorge Guzman
Sarah Hainer
George K Michalopoulos
Alina Ostrowska
Ira Fox
Edgar Naoe Tafaleng
Kazuki Takeishi
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of CL2022000967A1 publication Critical patent/CL2022000967A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES Y MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES HEPÁTICAS
CL2022000967A 2019-10-16 2022-04-14 Composiciones y métodos para el tratamiento de enfermedades hepáticas CL2022000967A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962915765P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
CL2022000967A1 true CL2022000967A1 (es) 2023-03-24

Family

ID=75538048

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000967A CL2022000967A1 (es) 2019-10-16 2022-04-14 Composiciones y métodos para el tratamiento de enfermedades hepáticas

Country Status (13)

Country Link
US (1) US20220362405A1 (es)
EP (1) EP4045094A4 (es)
JP (1) JP2022551987A (es)
KR (1) KR20220101631A (es)
CN (1) CN115209923A (es)
AU (1) AU2020367770A1 (es)
BR (1) BR112022007252A2 (es)
CA (1) CA3154460A1 (es)
CL (1) CL2022000967A1 (es)
IL (1) IL292221A (es)
MX (1) MX2022004625A (es)
WO (1) WO2021076566A1 (es)
ZA (1) ZA202205289B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof
WO2023133489A1 (en) * 2022-01-06 2023-07-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Transcriptional therapy based-lipid nanoparticles and mrna for the treatment of end-stage liver disease
WO2023214405A1 (en) * 2022-05-01 2023-11-09 Yeda Research And Development Co. Ltd. Reexpression of hnf4a to alleviate cancer-associated cachexia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981048B2 (en) * 2013-02-12 2018-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for the treatment and prevention of liver disease
US9682123B2 (en) * 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3224362B1 (en) * 2014-11-26 2024-09-25 The Regents of The University of California Therapeutic compositions comprising transcription factors and methods of making and using the same
CN105521482B (zh) * 2015-12-22 2020-07-14 中国人民解放军第二军医大学 联合应用HNF1α、HNF4α、FOXA3诱导分化治疗肝细胞癌
US20220152224A1 (en) * 2019-03-26 2022-05-19 The Penn State Research Foundation Methods and materials for treating cancer

Also Published As

Publication number Publication date
US20220362405A1 (en) 2022-11-17
EP4045094A1 (en) 2022-08-24
AU2020367770A1 (en) 2022-05-19
BR112022007252A2 (pt) 2022-08-23
WO2021076566A1 (en) 2021-04-22
IL292221A (en) 2022-06-01
ZA202205289B (en) 2024-09-25
MX2022004625A (es) 2022-07-11
CN115209923A (zh) 2022-10-18
CA3154460A1 (en) 2021-04-22
KR20220101631A (ko) 2022-07-19
EP4045094A4 (en) 2024-02-21
JP2022551987A (ja) 2022-12-14

Similar Documents

Publication Publication Date Title
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CO2018011064A2 (es) Inhibidores de bromodominios
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
IL282251A (en) Compositions and methods for treatment of liver disease
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
ES2985639T3 (es) Métodos y composiciones farmacéuticas para el tratamiento de condrodisplasia relacionada con FGFR3
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
IL283295A (en) gli1 inhibitors as therapeutic agents